Publication updates 17 to 21 April 2023

1. Atogepant approved for Adults With Chronic Migraine

The U.S. Food and Drug Administration (FDA) has approved expanding the indication of #atogepant for the preventive treatment of #migraine in adults. The approval is based on the outcomes of the Phase 3 PROGRESS Clinical Trial. The drug is available in three strengths for the preventive treatment of episodic migraine – 10 mg, 30 mg, and 60 mg. Only the 60 mg dose is approved for the preventive treatment of chronic migraine.

2. Serum #procalcitonin level is independently associated with mechanical ventilation and case-fatality?

This study was designed to confirm the associations of #PCT with #covid19 disease severity outcomes in a large cohort. The models demonstrated increasing disease severity (ventilation and death) with increasing PCT levels. Even when adjusted for demographics, diabetes, pneumonia, antibiotic use, white blood cell count, and serum C-reactive protein levels, the risks remained relatively high for mechanical ventilation. These data suggest that higher PCT levels have independent associations with ventilation and in-hospital death in veterans with COVID-19 disease.

3. Higher HbA1c Concentrations in Diabetes Linked With Greater Risk of Dementia

A total of 253,211 participants were included in the study. The mean (SD) duration of follow-up was 5.9 (4.5) years. Participants were categorized based on the percentage of their #HbA1c measurements that fell into the following categories: less than 6%, 6% to less than 7%, 7% to less than 8%, 8% to less than 9%, 9% to less than 10%, and 10% or more. Participants with more than 50% of HbA1c measurements at 9% to less than 10% or 10% or more had greater risk of dementia. By contrast, participants with more than 50% of HbA1c concentrations less than 6%, 6% to less than 7%, or 7% to less than 8% had lower risk of #dementia. #Dementia risk was greatest among adults with cumulative #HbA1c concentrations of 9% or more.

4. FDA Approves New 3-Minute Treatment for Excessive Underarm #Sweating

The U.S. Food and Drug Administration (FDA) has approved an underarm patch applied temporarily in a doctor’s office that can curb #perspiration for up to four months. It is a prescription sodium patch with an adhesive overlay that’s applied to the underarms in a doctor’s office. Wearing the patch for up to three minutes can reduce excessive sweating for three to four months. It works by triggering a reaction between sodium in the patch and water in sweat to cause what’s known as “microthermal injury” to sweat glands.

5. Elevated high-sensitivity C-reactive protein for the prognosis of three-vessel cardiac disease in patients with type 2 diabetes

A total of 2734 patients with and without type 2 #diabetes having three-vessel cardiac disease were stratified based on the high-sensitivity C-reactive protein (#hs-CRP) levels (< 2?mg/L vs. ≥ 2?mg/L). The primary endpoint was major adverse cardiac and cerebrovascular events (MACCE). The median follow-up duration was 2.4 years.?The incidence of MACCE and all-cause death were significantly higher in the diabetic group. In the diabetic group, the incidence of MACCE was significantly higher in the high hs-CRP group than in the low hs-CRP group; no significant difference was found for all-cause death. In the non-diabetic group, the prevalence of MACCE was comparable between the two hs-CRP groups.

------------------------------------------------------------------------------------------------------------

#medicalaffairs?#medicalwriting?#medicalwriter?#medicalcontent??#medicalcommunications?#healthcarecommunications?#scientificwriting?#freelancemedicalwriter?#scicomms #medcomms